Early predictors of non-response to interferon in multiple sclerosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F12%3A11531" target="_blank" >RIV/00216208:11110/12:11531 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/12:11531

Výsledek na webu

<a href="http://dx.doi.org/10.1111/j.1600-0404.2012.01662.x" target="_blank" >http://dx.doi.org/10.1111/j.1600-0404.2012.01662.x</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Early predictors of non-response to interferon in multiple sclerosis

Popis výsledku v původním jazyce

Objective - To identify early clinical and MRI predictors of non-response to interferon (IFN) treatment in multiple sclerosis (MS). Methods - In 172 patients with relapsing-remitting MS treated with IFN beta, we evaluated prediction of future treatment non-response. Candidate predictors comprised disability and its sustained progression, relapse score (combining frequency and severity of relapses), brain volume change, brain parenchymal fraction, number of new T2 lesions, and T2 and T1 lesion volume within the initial year of treatment. Treatment non-response was evaluated as confirmed disability progression or overall average annual relapse score exceeding 1 over the following 5 years. Logistic regression model was adjusted for patient age, gender, disease duration and changes in treatment. Results - Ninety patients (52%) reached the status of IFN non-responders in years 2-6. Patients with >= 1 new T2 lesion and relapse score >= 2 (odds ratio >= 5.7) or those with >= 3 new T2 lesions

Název v anglickém jazyce

Early predictors of non-response to interferon in multiple sclerosis

Popis výsledku anglicky

Objective - To identify early clinical and MRI predictors of non-response to interferon (IFN) treatment in multiple sclerosis (MS). Methods - In 172 patients with relapsing-remitting MS treated with IFN beta, we evaluated prediction of future treatment non-response. Candidate predictors comprised disability and its sustained progression, relapse score (combining frequency and severity of relapses), brain volume change, brain parenchymal fraction, number of new T2 lesions, and T2 and T1 lesion volume within the initial year of treatment. Treatment non-response was evaluated as confirmed disability progression or overall average annual relapse score exceeding 1 over the following 5 years. Logistic regression model was adjusted for patient age, gender, disease duration and changes in treatment. Results - Ninety patients (52%) reached the status of IFN non-responders in years 2-6. Patients with >= 1 new T2 lesion and relapse score >= 2 (odds ratio >= 5.7) or those with >= 3 new T2 lesions

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Acta Neurologica Scandinavica

ISSN

0001-6314

e-ISSN

—

Svazek periodika

126

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

DK - Dánské království

Počet stran výsledku

8

Strana od-do

390-397

Kód UT WoS článku

000310545400005

EID výsledku v databázi Scopus

—